The economic impact of non-melanoma skin cancer: A review

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 8, 2010, Pages 888-896

  Mudigonda, Tejaswi ^a   Pearce, Daniel J ^b   Yentzer, Brad A ^b   Williford, Phillip ^b   Feldman, Steven R ^b  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Basal cell carcinoma; BCC; Care settings; Costs; Medicare; Non melanoma skin cancer; SCC; Squamous cell carcinoma; Treatments

Indexed keywords

IMIQUIMOD;

COST BENEFIT ANALYSIS; CURETTAGE; DRUG COST; ECONOMIC ASPECT; FROZEN SECTION; HUMAN; MEDICARE; PHYSICIAN; REVIEW; SKIN CANCER; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 77957370718     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0066     Document Type: Review

References (42)

1. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30:774-778. (Pubitemid 24157120)
2. Strom SS. Epidemiology of basal and squamous cell carcinoma of the skin. In: Miller MJ, Weber RS, Goepfert H, eds. Basal and Squamous Cell Skin Cancers of the Head and Neck. Baltimore: Williams & Wilkins; 1996:1-7.
3. Skidmore RA Jr, Flowers FP. Nonmelanoma skin cancer. Med Clin North Am 1998;82:1309-1323.
4. Green A. Changing patterns in incidence of non-melanoma skin cancer. Epithelial Cell Biol 1992;1:47-51.
5. Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 1989;262:2097-2100.
6. American Cancer Society. Cancer Facts & Figures 2000. Available at: http://www.cancer.org. Accessed August 3, 2010.
7. Freedberg KA, Geller AC, Miller DR, et al. Screening for malignant melanoma: a cost-effectiveness analysis. J Am Acad Dermatol 1999;41:738-745.
8. Gloster HM Jr, Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996;22:217-226.
9. National Cancer Institute. Surveillance Epidemiology and End Results. Cancer Cancer Statistics Review 1999. Available at: seer.cancer.gov. Accessed August 3, 2010.
10. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
11. Weinstock MA. Epidemiologic investigation of nonmelanoma skin cancer mortality: the Rhode Island Follow-Back Study. J Invest Dermatol 1994;102:6S-9S.
12. Weinstock MA, Bogaars HA, Ashley M, et al. Nonmelanoma skin cancer mortality. A population-based study. Arch Dermatol 1991;127:1194-1197.
13. Weinstock MA. Nonmelanoma skin cancer mortality in the United States, 1969 through 1988. Arch Dermatol 1993;129:1286-1290.
14. Chen JG, Fleischer AB Jr, Smith ED, et al. Cost of non-melanoma skin cancer treatment in the United States. Dermatol Surg 2001;27:1035-1038.
15. Fleischer AB Jr, Feldman SR, Barlow JO, et al. The specialty of the treating physician affects the likelihood of tumor-free resection margins for basal cell carcinoma: results from a multi-institutional retrospective study. J Am Acad Dermatol 2001;44:224-230.
16. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425-429.
17. Fleischer AB Jr, Feldman SR, White RE, et al. Procedures for skin diseases performed by physicians in 1993 and 1994: analysis of data from the National Ambulatory Medical Care Survey. J Am Acad Dermatol 1997;37:719-724.
18. Smith ES, Feldman SR, Fleischer AB Jr, et al. Characteristics of office-based visits for skin cancer. Dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions. Dermatol Surg 1998;24:981-985.
19. Roenigk RK, Ratz JL, Bailin PL, Wheeland RG. Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol 1986;12:860-665.
20. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989;15:315-328.
21. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992;26:976-990.
22. Kibarian MA, Hruza GJ. Nonmelanoma skin cancer. Risks, treatment options, and tips on prevention. Postgrad Med 1995;98:39-48.
23. Centers for Disease Control and Prevention. National Center for Health Statistics. National Ambulatory Medical Care Survey 1996. Public use data tape. Available at: ftp://ftp.cdc.gov/pub/Health-Statistics/NCHS/Datasets/NAMCS/. Accessed August 10, 2010.
24. Centers for Disease Control and Prevention. National Center for Health Statistics. National Hospital Discharge Survey. Available at: http://cdc.gov/nchs/nhds.htm. Accessed August 10, 2010.
25. Centers for Disease Control and Prevention. National Center for Health Statistics. National Survey of Ambulatory Surgery. 2010 Available at: http://www.cdc.gov/nchs/nsas.htm. Accessed August 10, 2010.
26. Chen JG, Fleischer AB Jr, Smith ED, et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 2001;27:1035-1038.
27. Manternach T, Housman TS, Williford PM, et al. Surgical treatment of nonmelanoma skin cancer in the Medicare population. Dermatol Surg 2003;29:1167-1169.
28. John CG, Yelverton CB, Polisetty SS, et al. Treatment patterns and cost of nonmelanoma skin cancer management. Dermatol Surg 2006;32:1266-1271.
29. Cook J, Zitelli JA. Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol 1998;39:698-703. (Pubitemid 28519021)
30. Bialy TL, Whalen J, Veledar E, et al. Mohs micrographic surgery vs traditional surgical excision: a cost comparison analysis. Arch Dermatol 2004;140:736-742.
31. Rogers HW, Coldiron BM. A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption. J Am Acad Dermatol 2009;61:96-103.
32. Wasserman Y. Physicians' Fee Reference 2008. Wasserman Medical Publishers: 2008.
33. Joseph AK, Mark TL, Mueller C. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare. Dermatol Surg 2001;27:955-959.
34. AAD and ASDS mobilize to address state-based regulation of office-based dermatologic surgery. Dermatology World 1999;9:8-9.
35. Vila H Jr, Soto R, Cantor AB, Mackey D. Comparative outcomes analysis of procedures performed in physician offices and ambulatory surgery centers. Arch Surg 2003;138:991-995.
36. Venkat AP, Coldiron B, Balkrishnan R, et al. Lower adverse event and mortality rates in physician offices compared with ambulatory surgery centers: a reappraisal of Florida adverse event data. Dermatol Surg 2004;30:1444-1451.
37. Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004;364:1766-1772.
38. Welch ML, Anderson LL, Grabski WJ. Evaluation and management of nonmelanoma skin cancer. The military perspective. Dermatol Clin 1999;17:19-28.
39. Smeets NW, Kuijpers DI, Nelemans P, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face-results of a retrospective study and review of the literature. Br J Dermatol 2004;151:141-147.
40. Rodriguez-Vigil T, Vazquez-Lopez F, Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol 2007;56:91-95.
41. Kuijpers DI, Thissen MR, Berretty PJ, et al. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg 2007;33:579-587.
42. Coldiron BM, Healy C, Bene NI. Office surgery incidents: what seven years of Florida data show us. Dermatol Surg 2008;34:285-291.